eligibility_summary
Adults ≥18 with consent, histo/cyto‑confirmed ES‑SCLC (≥50% SCLC if mixed) progressed after platinum and PD‑1/PD‑L1, eligible for single‑agent chemo, archival tumor tissue, ECOG 0–1. Exclude: prior trial participation, BI 764532 or DLL3 TcE/cell therapy, recent investigational study, untreated/symptomatic brain mets (treated, stable allowed), leptomeningeal disease, unresolved >G1 toxicity (exceptions), major recent/planned surgery, other active malignancy ≤2y (cured exceptions).
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT05990738 tests BI 764532 (obrixtamig) plus single‑agent chemotherapy (primarily topotecan) in relapsed/refractory extensive‑stage SCLC after platinum. BI 764532 is an IV bispecific T‑cell engager (antibody‑like biologic) that binds DLL3 on tumor cells and CD3 on T cells, creating an immune synapse to activate T‑cell–mediated cytotoxicity. Topotecan is a cytotoxic small‑molecule topoisomerase I inhibitor that blocks DNA religation, causing replication‑dependent DNA breaks and apoptosis, other single‑agent chemo per label may be used. Targets/pathways: DLL3 (Notch pathway ligand) on SCLC cells, CD3/TCR signaling on T cells, DNA replication/repair via topoisomerase I.